Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ.

Nature. 2008 Jun 26;453(7199):1258-61. doi: 10.1038/nature06956. Epub 2008 May 14.

PMID:
18480754
2.

H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis.

van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ.

PLoS Pathog. 2012 Sep;8(9):e1002914. doi: 10.1371/journal.ppat.1002914. Epub 2012 Sep 20.

3.

Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.

Singh A, Soliman ME.

Drug Des Devel Ther. 2015 Jul 31;9:4137-54. doi: 10.2147/DDDT.S81934. eCollection 2015.

4.

Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.

Baek YH, Song MS, Lee EY, Kim YI, Kim EH, Park SJ, Park KJ, Kwon HI, Pascua PN, Lim GJ, Kim S, Yoon SW, Kim MH, Webby RJ, Choi YK.

J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.

5.

Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".

Rungrotmongkol T, Malaisree M, Udommaneethanakit T, Hannongbua S.

Biophys Chem. 2009 Apr;141(1):131-2; author reply 133. doi: 10.1016/j.bpc.2009.01.009. Epub 2009 Feb 2. No abstract available.

PMID:
19231807
6.

Structural basis for oseltamivir resistance of influenza viruses.

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ.

Vaccine. 2009 Oct 23;27(45):6317-23. doi: 10.1016/j.vaccine.2009.07.017.

PMID:
19840667
7.

Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.

Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):432-6. doi: 10.1016/j.bbrc.2009.06.016. Epub 2009 Jun 10.

PMID:
19523442
8.

Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.

Woods CJ, Malaisree M, Pattarapongdilok N, Sompornpisut P, Hannongbua S, Mulholland AJ.

Biochemistry. 2012 May 29;51(21):4364-75. doi: 10.1021/bi300561n. Epub 2012 May 17.

PMID:
22574858
9.

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

Hurt AC, Holien JK, Parker MW, Barr IG.

Drugs. 2009;69(18):2523-31. doi: 10.2165/11531450-000000000-00000.

PMID:
19943705
10.

Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.

Park JW, Jo WH.

J Chem Inf Model. 2009 Dec;49(12):2735-41. doi: 10.1021/ci900348n.

PMID:
19957991
11.

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ.

Nature. 2006 Sep 7;443(7107):45-9. Epub 2006 Aug 16.

PMID:
16915235
12.

Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.

Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA.

PLoS Pathog. 2010 May 27;6(5):e1000933. doi: 10.1371/journal.ppat.1000933.

13.

In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.

Liu H, Yao X, Wang C, Han J.

Mol Pharm. 2010 Jun 7;7(3):894-904. doi: 10.1021/mp100041b.

PMID:
20420444
14.

Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.

Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG.

PLoS Pathog. 2008 Apr 11;4(4):e1000043. doi: 10.1371/journal.ppat.1000043.

15.

Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA.

J Virol. 2007 Nov;81(22):12418-26. Epub 2007 Sep 12.

16.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

17.

Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.

Du QS, Wang SQ, Chou KC.

Biochem Biophys Res Commun. 2007 Oct 19;362(2):525-31. Epub 2007 Aug 13.

PMID:
17707775
18.

Computational studies of H5N1 influenza virus resistance to oseltamivir.

Wang NX, Zheng JJ.

Protein Sci. 2009 Apr;18(4):707-15. doi: 10.1002/pro.77.

19.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

20.

In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir.

Karthick V, Shanthi V, Rajasekaran R, Ramanathan K.

Protoplasma. 2013 Feb;250(1):197-207. doi: 10.1007/s00709-012-0394-6. Epub 2012 Mar 6.

PMID:
22392098
Items per page

Supplemental Content

Write to the Help Desk